According to related research reports (30), remarkable clinical efficacy can be achieved using PD-1 inhibitors to treat Hodgkin’s lymphoma and other aggressive B-cell lymphomas (31, 32). This evidence concerns the gene PDCD1 and Hodgkins lymphoma.